A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

NSCLC

Interventions

BIOLOGICAL

GI-4000

subcutaneous injection, 40YU weekly for 3 weeks followed by monthly for 6 months them quarterly until recurrence

Trial Locations (1)

Memorial Sloan-Kettering Cancer Center, New York